Fight CRC Clinical Trial Finder

Date Trial Added
View:
NCT ID Title Phase Date Added Location Prior IO Allowed CRC-directed Status Drugs Tags
NCT ID
NCT05438342
TitleAn Expanded Clinical Study of Triple Therapy for Refractory Solid Tumors That Failed First-line Treatment for Recurrence and Metastasis Phase
Not Applicable
Date Added
2022-06-29
Location
China
Prior IO Allowed
Yes
CRC-directed
No
Status
Recruiting
Drugs
Chemotherapy,checkpoint immunotherapy, targeted therapy
Tags
MSI-H/ MMRd, MSS/ MMRp
NCT ID
NCT05611034
TitleIn Vivo Lung Perfusion (IVLP) for Colorectal Cancer Metastatic to Lung Phase
Phase 1
Date Added
2022-11-09
Location
Canada
Prior IO Allowed
Yes
CRC-directed
Yes
Status
Recruiting
Drugs
oxaliplatin
Tags
MSI-H/ MMRd, MSS/ MMRp
NCT ID
NCT05479812
TitleDose Escalation Study of WTX-124 as Monotherapy and in Combination With Pembrolizumab (Pembro) in Patients With Selected Advanced or Metastatic Solid Tumors Phase
Phase 1
Date Added
2022-07-29
Location
Arizona, United States
Florida, United States
Georgia, United States
Illinois, United States
Indiana, United States
New Jersey, United States
New York, United States
Oregon, United States
Texas, United States
Prior IO Allowed
Yes
CRC-directed
No
Status
Recruiting
Drugs
Pembrolizumab, WTX-124
Tags
MSI-H/ MMRd
NCT ID
NCT05487235
TitleA Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors Phase
Phase 1
Date Added
2022-08-04
Location
Argentina
Australia
Brazil
Canada
Korea, Republic of
New Zealand
Prior IO Allowed
Yes
CRC-directed
No
Status
Active, not recruiting
Drugs
Atezolizumab, GDC-1971, Omeprazole
Tags
MSI-H/ MMRd, MSS/ MMRp
NCT ID
NCT05491317
TitleA Safety and Antitumor Activity Trial of Immunoradiotherapy Combinations as a Treatment Option for Subjects With Metastatic Solid Tumors Phase
Phase 1, Phase 2
Date Added
2022-08-08
Location
France
Prior IO Allowed
Yes
CRC-directed
No
Status
Active, not recruiting
Drugs
Pembrolizumab
Tags
MSI-H/ MMRd, MSS/ MMRp
NCT ID
NCT05493683
TitleDisitamab Vedotin Combined With Tislelizumab in Advanced HER2 Positive Colorectal Cancer Phase
Phase 2
Date Added
2022-08-09
Location
China,China,China,China,China,China
Prior IO Allowed
Yes
CRC-directed
Yes
Status
Recruiting
Drugs
Disitamab vedotin, Tislelizumab
Tags
MSI-H/ MMRd, MSS/ MMRp
NCT ID
NCT04262687
TitleChemotherapy and Immunotherapy as Treatment for MSS Metastatic Colorectal Cancer With High Immune Infiltrate Phase
Phase 2
Date Added
2020-02-10
Location
France
Prior IO Allowed
No
CRC-directed
Yes
Status
Recruiting
Drugs
Bevacizumab, capecitabine, oxaliplatin, Pembrolizumab
Tags
MSS/ MMRp
NCT ID
NCT05205330
TitleA Phase Ib/IIa Study of CR6086 in Combination With Balstilimab in pMMR-MSS Metastatic Colorectal Cancer Patients Phase
Phase 2
Date Added
2022-01-25
Location
Italy
Prior IO Allowed
No
CRC-directed
Yes
Status
Recruiting
Drugs
AGEN2034, Balstilimab, CR6086
Tags
MSS/ MMRp
NCT ID
NCT05201612
TitlePembrolizumab and Olaparib in Homologous-recombination Deficient (HRD) Advanced Colorectal Cancer (CRC). Phase
Phase 2
Date Added
2022-01-21
Location
Spain
Prior IO Allowed
No
CRC-directed
Yes
Status
Unknown status
Drugs
Olaparib, Pembrolizumab
Tags
MSI-H/ MMRd, MSS/ MMRp
NCT ID
NCT03104439
TitleNivolumab and Ipilimumab and Radiation Therapy in MSS and MSI High Colorectal and Pancreatic Cancer Phase
Phase 2
Date Added
2017-04-07
Location
Massachusetts, United States
Prior IO Allowed
No
CRC-directed
Yes
Status
Recruiting
Drugs
Ipilimumab, Nivolumab, Opdivo, Yervoy
Tags
MSI-H/ MMRd, MSS/ MMRp